CA-A Cancer Journal for Clinicians

Papers
(The median citation count of CA-A Cancer Journal for Clinicians is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Breast cancer in a transgender man13986
Minority groups underrepresented in hematologic cancer trials12779
Evolution of community outreach and engagement at National Cancer Institute‐Designated Cancer Centers, an evolving journey12364
Cancer treatment and survivorship statistics, 20256708
Cancer statistics 2024: All hands on deck2021
Near majority of adults favor R ratings for films with smoking1946
Highlighting American Cancer Society‐funded research in CA: A Cancer Journal for Clinicians1574
Issue Information1197
503
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer433
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types360
Most patients with cancer are not undergoing germline genetic testing334
Multicancer detection tests: What we know and what we don’t know319
Breast cancer: The good, the bad, and an important call to effective risk reduction strategies240
Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach182
Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future167
Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine165
163
Issue Information114
More care needed for cancer caregivers98
Health insurance status and cancer stage at diagnosis and survival in the United States96
92
Reviewer acknowledgement 202592
Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial82
Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review81
The evolving landscape of tissue‐agnostic therapies in precision oncology80
Study assesses normal tissue effects after axillary radiotherapy for early breast cancer78
Medicaid expansion increases survival for patients with cancer71
Lung cancer screening guidelines: Smoking matters, not quitting71
Overlooked barriers to implementation of geriatric assessment68
Study identifies risk factors that may lead to secondary cancers68
Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma61
Does distance deter male fertility preservation?58
Interventional gastroenterology in oncology57
The contemporary management of cancers of the sinonasal tract in adults52
Prostate cancer statistics, 202551
Issue Information41
Issue Information41
Screening for lung cancer40
Cancer survivors at greater risk for bone fractures late in life39
From medical student to Editor: A note of thanks37
Issue Information34
Bilateral mastectomy may not reduce mortality risk34
Self‐collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline34
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance32
Breast Cancer Statistics, 202230
Clinical management of metastatic colorectal cancer in the era of precision medicine27
Chemotherapy‐induced taste changes affect nutrition, quality of life27
Prevention of device‐related infections in patients with cancer: Current practice and future horizons27
Issue Information27
Cancer treatment and survivorship statistics, 202225
American Cancer Society nutrition and physical activity guideline for cancer survivors25
Is active surveillance an alternative to surgery for some patients with esophageal cancer?24
22
Issue Information21
20
Better communication is key for quality‐of‐life improvement in low‐income and minority patients20
Cancer misinformation on social media19
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries17
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors17
Key issues face AI deployment in cancer care17
17
Social determinants of health and US cancer screening interventions: A systematic review16
Immunotherapy combination shows longer progression‐free survival than chemotherapy alone for patients with a rare type of metastatic colorectal cancer16
Issue Information15
14
Urothelial carcinoma: Perioperative considerations from top to bottom13
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach13
Geriatric assessment for the practicing clinician: The why, what, and how13
Global cancer statistics: A healthy population relies on population health13
Fertility counseling for reproductive‐age women with cancer should address gestational carriers10
Cancer statistics, 2025: A hinge moment for optimism to morph into hope?10
Radiotheranostics in oncology: Making precision medicine possible10
Smoking cessation support lags behind lung cancer screenings10
Carcinoma of unknown primary: Molecular tumor board‐based therapy9
9
Is mandated genetic counseling needed?9
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer8
Issue Information8
Reviewer acknowledgement 20228
Cancer statistics for A merican I ndian and A l8
The evolving landscape of salivary gland tumors7
7
Translating energy balance research from the bench to the clinic to the community: Parallel animal‐human studies in cancer7
Cancer disparities for LGBTQ+ patients identified more fully7
Study identifies signs and symptoms of colorectal cancer risk at younger ages6
Regorafenib as maintenance therapy showed significant delayed progression of non‐adipocytic soft tissue sarcomas6
Sustained weight loss may reduce cancer risk6
Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer6
Not only a Western world issue: Cancer incidence in younger individuals in the United Arab Emirates6
Issue Information6
New studies examine COVID ‐19 risks among cancer patients6
Update and new advances in fertility preservation and cancer5
5
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial5
5
Modern developments in germline pharmacogenomics for oncology prescribing4
4
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management4
Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 20254
Issue Information4
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians3
Erratum to “Cancer statistics, 2024”3
Erectile dysfunction common within the first year after rectal cancer surgery3
A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant3
Female erectile tissues and sexual dysfunction after pelvic radiotherapy: A scoping review3
Issue Information3
Osimertinib prolongs progression‐free lung cancer survival after chemotherapy3
Issue Information3
Colon cancer blood test effective for average‐risk population2
Issue Information2
Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature2
Cancer in rural America: Improving access to clinical trials and quality of oncologic care2
Cancer statistics for African American and Black people, 20252
2
Issue Information2
Breast cancer survivors face greater cardiometabolic risks2
Correction to “Cancer treatment and survivorship statistics, 2025”2
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology2
MCED blood test boosts cancer detection in symptomatic patients2
Most young female cancer survivors are at minimal risk for obstetric problems2
0.024067878723145